Log in
Enquire now
Advent Life Sciences

Advent Life Sciences

A venture capital and private equity firm investing in life science technology companies.

OverviewStructured DataIssuesContributors

Contents

adventls.com
Is a
Organization
Organization
Investor
Investor
Company
Company
Venture capital firm
Venture capital firm

Company attributes

Industry
Finance
Finance
Biology
Biology
Biotechnology
Biotechnology
Financial services
Financial services
Biopharmaceutical
Biopharmaceutical
Technology
Technology
Location
London
London
0
B2X
B2C
B2C
B2B
B2B
0
Number of Employees (Ranges)
11 – 500
Email Address
contact@adventls.com0
Phone Number
+4420793221000
Full Address
27 Fitzroy Square London W1T 6ES0
Investors
Aura Biosciences
Aura Biosciences
Founded Date
2005
0
Fax Number
+44 (0)20 7932 21740
Country
United Kingdom
United Kingdom
0

Venture Capital Firm attributes

Invested in
‌
Argá Medtech February 2024 Series B Funding Round
Moximed
Moximed
‌
Macrolide Pharmaceuticals
KaNDy Therapeutics
KaNDy Therapeutics
Iterum Therapeutics
Iterum Therapeutics
0
NeRRe Therapeutics
NeRRe Therapeutics
Vestagen Technical Textiles
Vestagen Technical Textiles
Axonics Modulation Technologies
Axonics Modulation Technologies
...

Other attributes

Company Operating Status
Active
Wikidata ID
Q59536112

Advent Life Sciences is a venture capital and private equity firm investing in life science technology companies that is headquartered in London, England and was founded in 2010. The firm typically invests in life science companies in the United Kingdom, Europe, and the United States. Sectors of the life science industry that Advent Life Sciences invests in are new drug discovery, enabling technologies, medical technologies, and medical diagnostics.

Notable investments made by Advent Life Sciences include: Algeta, Avila, Biocartis, CardiacAssist, CardiAQ Valve Technologies, CardioKine, Callnovo, CN Creative, Conatus Pharmaceuticals, EUSA Pharma, KuDos Pharmaceuticals, Micromet, PowderMed, RespiVert, Santarus, Speciality European Pharma, Thiakis, and UniQure.

Investment funds
Fund II

On October 28, 2014 Advent Life Sciences announced raising $235 million for their second venture capital fund for backing early and mid-stage life science companies. Raj Parek, a general partner at Advent Life Sciences, made the following statement regarding the firms second fund:

We thank our returning and new LPs for the strength of their support, which allowed us to raise the commitments for this Fund in a matter of weeks. The interest from LPs and demand for the Fund, particularly in current markets, is in large part a recognition of the scientific and medical entrepreneurs, CEOs and Management teams whose commitment, vision and energy is enabling our portfolio companies to bring important medical innovations to patients. It is a privilege to work with them.

Timeline

No Timeline data yet.

Associated Investment Funds

Accelerator Batches

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Advent Life Sciences

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.